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MigrationDipeptidyl peptidase 9 (DPP9) is a ubiquitously expressed member of the DPP4 gene and protease family.
Deciphering the biological functions of DPP9 and its roles in pathogenesis has implicated DPP9 in tumor biology,
the immune response, apoptosis, intracellular epidermal growth factor-dependent signaling and cell adhesion
and migration. We investigated the intracellular distribution of DPP9 chimeric ﬂuorescent proteins and
consequent functions of DPP9. We showed that while some DPP9 is associated with mitochondria, the strongest
co-localization was with microtubules. Under steady state conditions, DPP9 was not seen at the plasma
membrane, but upon stimulation with either phorbol 12-myristate 13-acetate or epidermal growth factor,
some DPP9 re-distributed towards the rufﬂing membrane. DPP9 was seen at the leading edge of the migrating
cell and co-localized with the focal adhesion proteins, integrin-β1 and talin. DPP9 gene silencing and treatment
with a DPP8/DPP9 speciﬁc inhibitor both reduced cell adhesion and migration. Expression of integrin-β1 and
talin was decreased in DPP9-deﬁcient and DPP9-enzyme-inactive cells. There was a concomitant decrease in
the phosphorylation of focal adhesion kinase and paxillin, indicating that DPP9 knockdown or enzyme inhibition
suppressed the associated adhesion signaling pathway, causing impaired cell movement. These novel ﬁndings
provide mechanistic insights into the regulatory role of DPP9 in cell movement, and may thus implicate DPP9
in tissue and tumor growth and metastasis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
While it is rare for a protease to cleave a peptide bond after a proline
residue, proteases of the dipeptidyl peptidase IV (DPP-IV/DPP4) family,
which includes DPP9, DPP8 andﬁbroblast activation protein (FAP), have
such an ability and exert signiﬁcant functions in the pathogenesis of
diabetes, tumor biology and immunoregulation [1–3]. DPP4 is the
most widely studied member of this family and DPP4 inhibitors are a
successful clinical therapy for type 2 diabetes [4]. The unique expression
of FAP has led to it being a potential marker of cancer and remodeling
tissues [5]. DPP8 and DPP9 have not been as extensively examined,
but roles for them are emerging with implications in cell biology and
disease, as recently reviewed [6].enylate kinase; CN-I, collagen-I;
epidermal growth factor; EGFP,
FAK, focal adhesion kinase; FAP,
europeptide Y; PARP-1, poly
te 13-acetate; SUMO1, Small
tenary Institute, Locked Bag No.
; fax: +61 2 95656101.
. Gorrell).
, Lowy Cancer Research Centre,
s, Australia.DPP9 is ubiquitously expressed in normal tissues from mouse,
human, baboon, cynomolgus monkey and Sprague Dawley rat [7,8].
The expression of DPP9 is altered in many disease conditions, such as
in liver disease [3,8,9], inﬂamed lungs [10], inﬂammatory bowel disease
[11] and chronic lymphocytic leukemia [12]. DPP8 and DPP9 differ from
similar proteases in subcellular localization as they are intracellular
whereas DPP4 and FAP are extracellular [13,14]. Very recently, an
enzymatically active long form of DPP9 was seen in the nucleus and
its nuclear localization motif delineated [15]. The precise subcellular
localization of DPP9 in quiescent, moving and stimulated cells needs
close investigation.
Emerging evidence points to the role of DPP9 in a number of cellular
processes, including extracellular matrix (ECM) interactions, prolifera-
tion and apoptosis [9,16]. Knockdown of DPP8 or DPP9 can induce
neuropeptide Y (NPY)-driven tumor cell death, mediated by poly
(ADP-ribose) polymerase-1 (PARP-1) and apoptosis-inducing factor
(AIF) [17]. HEK293T cells over-expressing DPP9 have impaired cell
adhesion and monolayer wound healing, suggesting a role for DPP9 in
cell adhesion and migration [16], but the underlying mechanisms re-
main elusive. The association of DPP9 with H-Ras [9] suggests a poten-
tial role in intracellular signaling and only the EGF/Akt pathway has
received attention [9]. DPP9 peptidase activity can be regulated by
interacting with small ubiquitin-related modiﬁer 1 (SUMO1), which
acts as an allosteric activator of DPP9 [18]. A peptide fragment which
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E67-interacting loop, acts as an allosteric inhibitor of DPP9 [19]. DPP8
and DPP9 enzyme activities are important in tumor biology [17,20,21]
and immunobiology [3,22–24]. Interestingly, the ﬁrst report on DPP9
enzyme-inactive mice, which mimics in vivo selective DPP9 inhibition,
shows that DPP9 enzyme activity is essential for early neonatal survival
in mice [25].
Cell movement is fundamental in development and in most biologi-
cal processes including wound healing, tissue regeneration, tumor
growth and metastasis and immune responses [26,27]. Focal adhesion
(FA) is a crucial cell adhesion complex consisting of integrins clustering
via talin–vinculin interactions aswell as the Arp2/3 complex. Vinculin is
linked with the actin cytoskeleton [28,29]. In cell migration, FA
complexes are usually formed during protrusion of the leading edge of
a cell, with roles in maintaining attachments to ECM and acting as
signaling centers from which numerous signaling molecules regulate
cell adhesion and migration [30,31]. One well-characterized pathway
is through focal adhesion kinase (FAK) by the association andphosphor-
ylation of several proteins. Elevated FAK expression occurs in a variety
of human tumors, through regulating cell mobility, invasion and surviv-
al [32]. A critical event in integrin-mediated FAK signaling is phosphor-
ylation of Tyr397 [33]. Paxillin is a multi-domain adaptor protein that
localizes primarily to FA sites, recruiting signaling molecules to coordi-
nate downstream signaling [34,35]. Phosphorylation of paxillin by FAK
modulates FA formation and haptotactic migration via association
with talin [36]. Thus, FAK and paxillin have a pivotal role in regulating
cell movement. DPP9 over-expression has previously been reported to
impair cell adhesion and migration [16]. However, the precise role of
endogenous DPP9 in FA dynamics and cell movement remains to be
elucidated.
Despite recent progress, DPP9's role in cell adhesion and migration
remains poorly understood. This study investigated the precise
subcellular localization of DPP9 and explored the role and mechanisms
of action of DPP9 in cell movement.
2. Materials and methods
2.1. Cell culture and cell stimulation
Huh7 (JCRB0403) and HeLa (ATCC® CCL-2™) cells weremaintained
in complete Dulbecco'sModiﬁed Eagle'sMedium (DMEM) supplement-
ed with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml
streptomycin. Cells at a conﬂuency of 50–60% were transfected using
Lipofectamin®2000 (11668019; Invitrogen, Carlsbad, CA).
For cell stimulation, Huh7 cells were serum-starved for 16 h and then
incubated at 37 °C with Phorbol 12-myristate 13-acetate (PMA; P1585;
Sigma-Aldrich, St Louis, MO) at 0, 300, and 500 nM for 15, 30, 60 min or
epidermal growth factor (EGF; 236-EG; R&D Systems, Minneapolis,
Minnesota, USA) at 0, 10, and 20 ng/ml for 15, 30, and 45 min.Table 1
Antibodies used for Western blotting.
Name Isotype D
DPP9 Mouse IgG 1
Talin Mouse IgG1 1
Vinculin Mouse IgG1 1
Integrin-β1 Rabbit IgG 1
p-FAK (Tyr397) rabbit IgG 1
FAK Rabbit IgG 1
p-Paxillin (Tyr118) rabbit IgG 1
Paxillin Rabbit IgG 1
p-Akt (Ser473) rabbit IgG 1
Akt Rabbit IgG 1
β-Actin Rabbit IgG 1
GAPDH Mouse IgG 1
Anti-mouse immunoglobulins/HRP Rabbit 1
Anti-rabbit immunoglobulins/HRP Goat 12.2. Plasmids, siRNA knockdown, inhibitor treatment and antibodies
Cloning of the 863 amino acid form of DPP9 into pEGFP-N1 was
described [14,16]. The enzyme-inactive mutant of DPP9 was generated
as described by alanine replacement of the catalytic serine residue at
position 729 [16]. Cells were transiently transfected 40 h before assay
to over-express wild-type DPP9-enhanced green ﬂuorescent protein
(wtDPP9-EGFP) or enzyme-inactive mutant DPP9 (mutDPP9-EGFP)
chimeric proteins, or mock transfected with Lipofectamine 2000 only.
For DPP9 silencing, Huh7 cells were transfectedwith the siRNA oligonu-
cleotide DPP9-6 (L-005856; Dharmacon, Massachusetts, USA) or the
ON-TARGETplus™ Non-Targeting siRNA-2 (D00181002; Dharmacon)
as a control. Cells were analyzed 48 h after siRNA transfection by
Western blotting and quantitative PCR [3]. Cells were analyzed 6 h
after treatment with 8 μM DPP8/DPP9 speciﬁc inhibitor 1G244 [37]
(Y0432; AK Science, Union City, California, USA). DPP9 enzyme assay
has been described [25]. Antibodies and normal IgG controls are
shown in Table 1 (for Western blotting) and Table 2 (for immunoﬂuo-
rescence staining).
2.3. Immunoﬂuorescence staining, confocal microscopy, time-lapse
microscopy
Cells grown on ﬁbronectin (BD Bioscience, Maryland, USA)-coated
coverslips were ﬁxed with 4% paraformaldehyde for 15 min and then
permeabilized with 0.2% Triton-X-100 in PBS for 10 min. After blocking
with 2% BSA/PBS plus 10% normal serum for 30 min, cells were treated
with primary antibody or normal IgG (Table 1) for 90 min in a humidi-
ﬁed chamber, followed by three PBS washes and subsequent staining
for 90 min with secondary antibodies. Organelle markers include
MitoTracker® Red CM-H2Xros (M-7513, 50 nM; Invitrogen) for
mitochondria, β-tubulin antibody for microtubules and wheat germ
agglutinin (WGA)-Alexa Fluor® 594 Conjugate (W11262, 1 mg/ml;
Invitrogen) for plasma membrane or golgi apparatus stain without
or with permeabilization, respectively. Cells were mounted with
ProLong® Gold Antifade Reagent with DAPI (P-36931; Invitrogen) for
nuclear stain. All incubations were at room temperature. Confocal
images were captured using a Leica TCS SP5 confocal microscope. Four
lasers, at 405, 488, 561 and 633 nm, were used for excitation. A Plan
Apo 63×/1.2 water objective lens and frame-by-frame sequential
scanning with individual lasers were used for imaging. Optimized ﬂuo-
rescence ﬁlter sets and adjustable photomultiplier detector slit widths
were used to minimize spectral bleed-through artifacts [39]. All images
were processed using Image J software (National Institutes of Health,
Bethesda, MA, USA). The number of active FA sites indicated by
phosphorylated FAK or paxillin was counted using Image J software
and normalized to cell area. Time-lapse microscopy used the
DeltaVision Elite microscope (GE Healthcare). Huh7 cells grown on ﬁ-
bronectin and transfected with wtDPP9-EGFP were imaged every 30 silution Supplier Catalog
:2000 OriGene TA503937
:3000 Sigma-Aldrich T3287
:3000 Sigma-Aldrich T9131
:3000 Cell Signaling Technology #4706
:1000 Cell Signaling Technology #3283
:2000 Cell Signaling Technology #3285
:1000 Cell Signaling Technology #2541
:2000 Cell Signaling Technology #2542
:1000 Cell Signaling Technology #9271
:2000 Cell Signaling Technology #9272
:5000 Sigma-Aldrich A-2103
:5000 Sigma-Aldrich G8795
:5000 DAKO P0161
:5000 DAKO P0448
Table 2
Antibodies used for immunoﬂuorescence staining.
Name Isotype Dilution Supplier Catalog
β-Tubulin Mouse IgG1 1:400 Sigma-Aldrich T8328
Talin Mouse IgG1 1:400 Sigma-Aldrich T3287
Vinculin Mouse IgG1 1:400 Sigma-Aldrich T9131
Integrin-β1 Rabbit IgG 1:200 Gamble, Sydney 61-2C4 [38]
p-FAK (Tyr397) Rabbit IgG 1:100 Cell Signaling Technology #3283
p-Paxillin (Tyr118) Rabbit IgG 1:100 Cell Signaling Technology #2541
Normal IgG Mouse 1:200 Sigma-Aldrich 15381
Normal IgG Rabbit 1:200 Sigma-Aldrich 15006
Alexa Fluor®488 anti-mouse Donkey 1:200 Invitrogen A-21202
Alexa Fluor® 594 anti-rabbit Goat 1:200 Invitrogen A-11037
Alexa Fluor® 594 anti-mouse Goat 1:200 Invitrogen A-11005
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into movies using Volocity (Version 6.3, PerkinElmer, Massachusetts,
USA). Immunoﬂuorescence staining and imaging were repeated three
times.
2.4. Super-resolution microscopy
Cells grown on ﬁbronectin and transfected with wtDPP9-EGFPwere
ﬁxed with ice-cold methanol, permeabilized with 0.2% Triton-X-100
and blocked with 3% BSA/PBS. Cells were then incubated with anti-β-
tubulin antibody (1:400) at 4 °C overnight and then Alexa Fluor® 647
goat anti-mouse IgG (1:400) for 2 h at room temperature. Reconstruct-
ed super-resolved images based on single molecule localization were
captured on a Leica SR-GSD (Super Resolution-Ground State Depletion)
microscope [40]. Immunoﬂuorescence staining and imaging were
repeated three times.
2.5. Immunoblotting
Cells werewashedwith ice-cold PBS and transferred to ice-cold lysis
buffer (50mMTris–HCl pH 7.6, 1mMEDTA, 1mMMgCl2, 150mMNaCl,
1% Triton-114, 10% glycerol, 1 × complete protease inhibitor cocktail
(04693159001; Roche Applied Science, Indianapolis, IN, USA) and 1 ×
phosphatase inhibitor cocktail (04906845001; Roche Applied Science).
Protein concentration was determined using the Micro BCA Protein
Assay Kit (#3235; Thermo Scientiﬁc, Waltham, Massachusetts, USA).
25 μg of protein from cell lysate was resolved on 4–12% Bis-Tris
SDS-PAGE (NP0323PK2; Invitrogen) followed by immunoblotting [41].
Immunodetection was performed by chemiluminescence with
Immobilon Western Chemiluminescent HRP Substrate (WBKLS0500;
Merck Millipore, Billerica, MA, USA) and imaged on a ChemiDoc™MP
System (Bio-Rad, Richmond, CA, USA). Band intensity was quantiﬁed
with Image J software for three independent experiments.
2.6. Cell adhesion assay
This method is modiﬁed from previous publications [39,42]. Brieﬂy,
either ﬁbronectin or collagen-I (A104830; Invitrogen) at 30 μg/ml
was incubated in 96-well microplates for 60 min. After blocking with
10mg/ml heat-denatured BSA for 30min, 4 × 104 cells perwell were in-
cubated at 37 °C for 30 min. Non-adherent and loosely attached cells
were then washed with PBS and the remaining adherent cells were
ﬁxed with 4% formaldehyde for 20 min and stained with 0.03% (w/v)
crystal violet (V5265; Sigma-Aldrich) for 60min, followed by solubiliza-
tion in 10% (v/v) acetic acid for 5 min. Incubations were at ambient
temperature unless stated. Absorbance at 570 nm was measured in a
Fluostar® microplate reader (BMG Labtech, Offenburg, Germany). A
standard curve of known numbers of cells was used to calculate percent
adherent cells. The assays on siRNA knockdown and inhibitor treatment
were performed four and three times, respectively, in triplicate.2.7. Monolayer scratch assay of cell migration
Cell monolayers were grown on coverslips that were either uncoat-
ed or coated with ﬁbronectin or collagen-I at 30 μg/ml and then
scratched as described [39]. Cells were then incubated with 1% fetal bo-
vine serum in DMEM to minimize cell proliferation, apoptosis and cell
detachment. After 20 h, cells were either imaged under a bright ﬁeld
microscope (Nikon Elipse TS100) or were immunostained for confocal
microscopy. The migration rate, calculated using Image J, was the
number of cells in the scratch area divided by the width of the scratch
area. Migration assays on siRNA knockdown and inhibitor treatment
were performed four and three times, respectively, in triplicate.
2.8. Statistics
Each experiment was repeated three or four times. Results are
expressed as mean and SD. Statistical analyses were performed using
GraphPad Prism (GraphPad Software, La Jolla CA). Differences among
groups were analyzed using one-way ANOVA and pairwise compari-
sons were performed using Student's t-test. P-values b0.05 were
considered signiﬁcant.
3. Results
3.1. Co-localization of active and inactive DPP9 with microtubules
Over-expressed wtDPP9-EGFP and mutDPP9-EGFP were both
detected at approximately 122 kDa (Fig. 1A, band 1), representing
~16-fold greater levels than endogenous DPP9 at 95 kDa (Fig. 1A,
band 2) in transfected cells. This level of DPP9-over-expression is
comparable with our previous data [9].
Confocal microscopy superﬁcially showed diffuse intracellular DPP9
in Huh7 cells transfectedwithwtDPP9-EGFP. However, detailed inspec-
tion revealed several features of potential functional signiﬁcance.
Co-staining DPP9-EGFP with various organelle markers showed that
DPP9-EGFP was distinct from both the plasmamembrane and golgi ap-
paratus (Fig. 1B) and showed some co-localization with mitochondria
(Fig. 1C). In some cells, DPP9-EGFP formed a strand-shaped pattern
that co-localized with microtubules (Fig. 1D). Cells with a low level of
DPP9 over-expression similarly exhibited co-localization with microtu-
bules and mitochondria (data not shown). As the resolving power of
conventional confocal microscopy is limited, we assessed the associa-
tion between DPP9 and microtubules using super-resolution microsco-
py, which permits far greater accuracy in subcellular localization by
resolving details to nanometer scale. Super-resolved images from a
Leica SR-GSD showed single molecule co-localization (arrows) of
DPP9-EGFPwithmicrotubules (Fig. 1E). To investigatewhether enzyme
activity affects the localization of DPP9, enzyme-inactive mutDPP9-
EGFP was transiently transfected into Huh7 cells and displayed the
same expression patterns as wtDPP9-EGFP (Fig. 1F).
AD
DAPI wtDPP9-EGFP
mitochondria merge
plasma membrane golgi
mitochondria microtubules
DAPI mutDPP9-EGFP
DAPI wtDPP9-EGFP
plasma membrane golgi
C
DAPI wtDPP9-EGFP
microtubules merge
F
E
B
microtubules
merge
wtDPP9-EGFP
kDa
wtDPP9
 EGFP
mutDPP9
   EGFP
vector
EGFPmock
115
140
80
Mr
1
2
Fig. 1. Co-localization of active and inactive DPP9 with microtubules. Huh7 cells adherent to ﬁbronectin-coated coverslips were transfected with wtDPP9-EGFP (B–E) or mutDPP9-EGFP
(F) (green) and cell nuclei counterstained with DAPI (blue). (A) Western blotting showed ~16-fold greater levels of wt and mut DPP9-EGFP (122 kDa, band 1) than endogenous DPP9
(95 kDa, band 2) in transfected cells. (B) wtDPP9-EGFP localized separately to WGA-stained plasma membrane and golgi apparatus without or with permeabilization, respectively.
(C) DPP9 co-localized with some MitoTracker®-stained mitochondria. (D) In some cells, DPP9 formed a strand-shaped pattern (arrows) that co-localized with β-tubulin-labeled micro-
tubules (red). (E) Super-resolved images from a Leica SR-GSD showed single molecule co-localization (arrows) of wtDPP9-EGFPwith β-tubulin-labeledmicrotubules (red). (F) The same
molecular localization patterns were observed in Huh7 cells transfected with enzyme-negative mutDPP9-EGFP and stained as in (B–D) to visualize plasma membrane, golgi apparatus,
mitochondria and microtubules (red). WGA=Wheat Germ Agglutinin. Scale bars: 15 μm (B–D, F); 5 μm (E). Images are representative of three independent experiments.
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cell stimulation with PMA and EGF
Confocal microscopy showed that DPP9 is intracellular in steady-
state cells. We next assessed whether DPP9 re-localizes following cell
stimulation. We previously showed that DPP9 associates with H-Ras
and attenuates the EGF-mediated PI3K/Akt pathway [9]. It is known
that PMA can induce membrane rufﬂing, which is important for cellspreading and migration [43,44]. Therefore, we investigated whether
the subcellular distribution of DPP9 in Huh7 cells can be modulated by
PMA or EGF. After 60min of 500 nMPMA stimulation, DPP9was readily
seen near the rufﬂing membrane, evidenced by prominent EGFP ﬂuo-
rescence at parts of the cell surface (Fig. 2A). DPP9-EGFP near the rufﬂes
was also seen after 20 ng/ml EGF stimulation for 45 min (Fig. 2A), but
not after low glucose (5.56 mM D-glucose) treatment (Fig. 2A). Plasma
membrane recruitment of DPP9 following EGF stimulation was also
PMA
A
Untreated
B
C
00:00:00 00:02:00 00:04:00 00:06:00
EGF Low glucose
EGF
EGF
EGF
D plasma membranewtDPP9-EGFP merge
plasma membranewtDPP9-EGFP merge
Fig. 2. Re-distribution of DPP9 to the rufﬂing plasma membrane upon PMA- and EGF-mediated cell stimulation. Huh7 cells on ﬁbronectin-coated coverslips were transfected to over-ex-
press wtDPP9-EGFP (green). (A) Cells were stimulated with 500 nM PMA for 60 min or 20 ng/ml EGF for 45 min and DPP9 re-distribution towards the rufﬂing membrane (arrows) was
observed. (B) Time-lapsemicroscopy of live cells stimulatedwith 20 ng/ml EGF, showing snapshots every 2minwith arrows pointing to the rufﬂingmembrane. (C, D) Following 20 ng/ml
EGF stimulation for 45min, cells were plasmamembrane-stained usingWGA (red) and then imaged by confocal (C) or super-resolution (Leica SR-GSD; D)microscopy to show that DPP9
localized very close to the inside of the rufﬂingmembrane (outlined inwhite) butwasnot physically situated in or on themembrane. EGF=EpidermalGrowth Factor; PMA=phorbol 12-
myristate 13-acetate; WGA=Wheat Germ Agglutinin. Scale bars: 15 μm (A, B), 9 μm (C), 5 μm (D). Images are representative of three independent experiments.
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1). Upon visualization of plasma membrane with WGA-Alexa Fluor
594 co-staining and treatment of cells with 20 ng/ml EGF for 45 min,
DPP9-EGFP was located near the rufﬂing membrane and appeared co-
localized with the plasma membrane (Fig. 2C). However, super-
resolution microscopy more precisely localized DPP9-EGFP in the
cytoplasm near the plasma membrane, but not physically situated in
or on the membrane (Fig. 2D).
3.3. Location of DPP9 at the leading edge of migrating cells and association
with the focal adhesion complex
Having shown the re-distribution of DPP9 towards the membrane,
we next asked whether this localization reﬂects the function of DPP9
in regulating cell movement.We ﬁrst performed time-lapsemicroscopy
of live Huh7 cells transfected with wtDPP9-EGFPwhere ﬂuorescent sig-
nal accumulated near the edge of cells in the direction of movement
(Fig. 3A and Supplementary Movie 2), indicating that DPP9-EGFP was
accumulated along the leading edge of the plasma membrane but was
diffuse at the trailing edge of the cell. During migration, adhesion com-
plexes assemble at the leading edge and disassemble at the trailingedge, co-ordinating with actin polymerization and contraction [45].
The most pronounced adhesion complex is the FA consisting of
integrins, talin and vinculin and we next examined DPP9 localization
in relation to the FA complex. Interestingly, DPP9 displayed a polarized
localization. DPP9was usually diffuse on one side of a cell andwasmore
punctate (arrows) at the edge of the other side (Fig. 3B). At the punctate
edge, integrin-β1 was enriched and was co-localized with DPP9-EGFP. A
very similar expression pattern was also observed with DPP9-EGFP and
talin, whereas DPP9-EGFP generally was seen adjacent to vinculin and
the co-localization was less apparent at the edge of the cell (Fig. 3B).
HeLa cells transfected with DPP9-EGFP showed the same co-localization
pattern with integrin-β1 and talin (Supplementary Fig. S1). Furthermore,
to encourage cell migration, DPP9-EGFP-transfected-HeLa cell mono-
layers were scratched and then stained for FA proteins. Cells migrating
into the scratch/wound exhibited a similar expression pattern to that de-
scribed above, showing co-localizationwith integrin-β1 and talin but less
with vinculin at the edge of the cell (Fig. 3C). It is important to note that
cells shown in Fig. 3B and C had morphological characteristics similar to
those of the Huh7 cells in live-cell imaging (Fig. 3A), suggesting that the
co-localization of DPP9-EGFP with integrin-β1 and talin was occurring
at the leading edge. Therefore, DPP9 appears to be associated with the
AC
00:00:00 00:14:51 00:29:51 00:44:52 01:04:55
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i ii
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Fig. 3. Location of DPP9 near the leading edge of migrating cells and association with the focal adhesion complex. Huh7 (A, B) or HeLa (C) cells on ﬁbronectin-coated coverslips were
transfected to over-express wtDPP9-EGFP (green). (A) Time-lapse microscopy of live cells at the stated times with arrows pointing to the leading edge of the cell. (B) DPP9 was usually
diffuse on one side of a cell andwasmore punctate (arrows) at the edge of the other side. Three proteins of the focal adhesion complex, integrin-β1 (i), talin (ii) and vinculin (iii) were co-
immunostained (red). Greater magniﬁcation of the boxed areas (right panels) shows DPP9 co-localized with integrin-β1 and talin but not with vinculin at the cell edge. (C) Following a
scratch in a cell monolayer (scratch edges are indicated by white lines), DPP9 was co-localized with integrin-β1 (i) and talin (ii), while was adjacent to vinculin (iii) (red) at the leading
edges of cells migrating into the scratch (arrows). The lower panels depict a magniﬁed migrating cell that is imaged in the panels above. Scale bars: 30 μm (A), 15 μm (B, C). Images are
representative of three independent experiments.
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476 H. Zhang et al. / Biochimica et Biophysica Acta 1853 (2015) 470–480FA complex, possibly through direct or indirect physical interaction with
integrin-β1 and talin, at the leading edge of migrating cells.
3.4. Cell adhesion is impaired by down-regulation of DPP9 or inhibition of
DPP9 enzyme activity
The association of DPP9 with focal adhesion complex proteins at the
leading edge of migrating cells was further assessed by in vitro cell
adhesion and migration assays. We explored the impact of both DPP9
knockdown and DPP9 enzyme inhibition on cell movement, both of
which target all forms of endogenousDPP9. ADPP9 knockdownmethod
by siRNA transfection was developed and conﬁrmed at bothmRNA and
protein levels. Quantitative PCR showed 87.5% down-regulation of
DPP9 at themRNA level (Fig. 4A) and no change in DPP8mRNA expres-
sion (Fig. 4B). Western blotting with a monoclonal DPP9 antibody
showed a 94% reduction in DPP9 protein (Fig. 4C) after DPP9 siRNA
transfection. The DPP8/DPP9 speciﬁc inhibitor 1G244 produced up
to 82.5% reduction in dipeptidyl peptidase activity in Huh7 cells
(Fig. 4D), conﬁrming effective enzyme inhibition, whereas a DPP4-
speciﬁc inhibitor, sitagliptin, had no effect. Both siRNA and inhibitor
treatments had no effect onHuh7 cell apoptosis and death, asmeasured
by ﬂow cytometry (data not shown).
Cell adhesion assays were then carried out after treatment with
DPP9 siRNA or 1G244. Huh7 cells displayed signiﬁcantly less adhesion
to either ﬁbronectin or collagen-I than control cells after DPP9 knock-
down (Fig. 4E, left) and enzyme activity inhibition (Fig. 4E, right).
3.5. Cell migration is impaired by down-regulation of DPP9 or inhibition of
DPP9 enzyme activity
Consistent with cell adhesion impairment, in vitro cell migration as-
says showed that Huh7 cell monolayers on collagen-I or ﬁbronectin
closed the scratch wound more slowly after DPP9 knockdown (Fig. 5A)D
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Fig. 4. Down-regulation of DPP9 and inhibition of DPP9 enzyme activity impair cell adhesion.
for 48 h, or treated with 8 μM 1G244 to inhibit DPP9 enzyme activity (or vehicle control, 0.08%
DPP9 mRNA (A), whereas DPP8 mRNA levels were unchanged (B). DPP9 siRNA also signiﬁ
reduced hydrolysis of the dipeptidyl peptidase substrate, H-Gly-Pro-pNA, by 82.5% while the
collagen-I (CN-I) coated plastic was signiﬁcantly reduced after either siRNA transfection (lef
experiments. Cell adhesion data (E; mean and SD) on siRNA knockdown and inhibitor trea
* p b 0.05, ** p b 0.01, ***p b 0.001.or DPP9 enzyme inhibition (Fig. 5B), consistent with an impaired migra-
tion process. Migration rate data was converted to ratios to overcome
inter-assay variability (raw data is presented in Supplementary Fig. S2).
The percentage reduction in both adhesion and migration rates
within matched treatment pairs was quantiﬁed (Table 3), showing
comparable data by DPP9 down-regulation and enzyme inhibition,
indicating that DPP9 enzyme activity is necessary for DPP9-mediated
regulation of Huh7 cell adhesion and movement.
3.6. Levels of integrin-β1, talin and phosphorylation of FAK and paxillin are
reduced by down-regulation of DPP9 or inhibition of DPP9 enzyme activity
Given that down-regulation of DPP9 and inhibition of its enzyme
activity impair cell adhesion and migration, we next investigated the
potential mechanisms involved. As DPP9 associates with FA proteins,
we explored whether the expression of FA proteins and/or the related
adhesion signaling pathway was modulated. Western blot analysis
showed ~30% and 27% reduction in integrin-β1 expression after DPP9
gene silencing and enzyme inhibition, respectively (Fig. 6A). Talin
expression was decreased by 15% by either treatment, compared with
corresponding controls, while vinculin was not signiﬁcantly changed
at the protein level by either treatment (Fig. 6A). Densitometry of
Western blot analysis is shown in Supplementary Fig. S3.
To investigate the related adhesion signaling pathway, we then
studied the phosphorylation level of signaling molecules. FAK is a key
factor in controlling FA dynamics. Densitometry of Western blotting
analysis showed that phosphorylation of FAK (p-FAK) at Tyr397, a
major phosphorylation site during FAK activation, was reduced by 11%
and 25% in DPP9 siRNA transfected and inhibitor treated cells, respec-
tively (Fig. 6A), indicating that DPP9 is important for activation of FAK
in both models. In addition to FAK, we assessed the activation state of
a downstream substrate, paxillin, but phosphorylation at Tyr118 was
not detectable by immunoblotting under these experimental conditionsanti-DPP9 95
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phosphorylation at Ser473 by 19%, which was not evident by DPP9
down-regulation (Fig. 6A).Table 3
Percentage (%) reduction in cell adhesion andmigration on collagen-I (CN-I) andﬁbronec-
tin (FN) coated plastic after DPP9 knockdown or activity inhibition. The raw data is
presented in Supplementary Fig. S2.
Adhesion Migration
CN-I FN CN-I FN
DPP9 knockdown 49.3% 49.1% 43.5% 30.6%
DPP9 activity inhibition 55.8% 48.9% 43.6% 26.4%To further examine DPP9-mediated down-regulation of FAK phos-
phorylation at the cellular level, Huh7 cellswereﬁxed afterDPP9 knock-
down or enzyme inhibition and immunostained for p-FAK (Tyr397).
Active FA sites, indicated by p-FAK staining, were quantiﬁed. Consistent
with the immunoblotting result, a decreased ratio of active FA sites to
cell area was seen in DPP9-knockdown cells (Fig. 6B) and in DPP9-
activity-inhibited cells (Fig. 6C), compared with each control. We then
analyzed the phosphorylation level of paxillin (p-paxillin) at Tyr118
using the samemethod described above. Concordant datawas obtained
using p-paxillin to enumerate active FA sites (Fig. 6B and C, lower
panels). These data demonstrate that DPP9 enzyme activity has a
regulatory role on FA proteins and events leading to phosphorylation
of FAK and paxillin.
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The present study is the ﬁrst detailed investigation of the subcellular
localization of DPP9 and shows some co-localization between DPP9 and
microtubules. Furthermore, we provide evidence for an important role
of DPP9 in the regulation of cell movement. The observation that DPP9accumulated towards the rufﬂing membrane and at the leading edge
of migrating cells is novel. Both silencing DPP9 and enzyme inhibition
resulted in impaired cell adhesion and migration. The associations
of DPP9 with the FA proteins integrin-β1 and talin provide the
ﬁrst mechanistic insight into the role of DPP9 in cell adhesion and
migration. Modulating the expression of these key adhesion proteins
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these processes.
Protein functions often correspond with their subcellular localiza-
tion.Microtubules function in a variety of biological processes, including
cell motility, the intracellular transport of organelles and proteins and
the separation of chromosomes during mitosis [46]. Tubulins were ob-
served proximal to DPP9 and thus microtubules might facilitate DPP9
transportation towards a speciﬁc subcellular location upon cell activa-
tion, possibly the rufﬂing membrane. A mitochondrial enzyme, adenyl-
ate kinase 2 (AK2), was previously identiﬁed as a candidate substrate
for DPP8 and DPP9 and the co-localization of AK2 with DPP9 was
reported [47]. Here in this work, DPP9 showed some co-localization
with mitochondria, providing further evidence that DPP9 has access to
mitochondrial enzymes that may be substrates. The exact relationships
of DPP9 with both microtubules and mitochondria require further
investigation.
DPP4 and FAP have been found at invadopodia-like protrusions [48].
While DPP8 and DPP9 have been reported to be loosely bound on the
surface of immune cells under certain circumstances [49], we observed
DPP9 near the rufﬂing membrane upon cell stimulation but saw no ev-
idence of DPP9 physically situated in or on the cell surface of Huh7 cells.
These co-localization experiments performed on epithelial cells thus
need investigating in other cell types. The results from cell adhesion
and migration assays support this hypothesis and concordant data
were obtained in both DPP9 knockdown and enzyme inhibition exper-
iments. Notably, 1G244 inhibits both DPP8 and DPP9 enzyme activity
whereas siRNA knockdown speciﬁcally down-regulates DPP9. Since
inhibition of DPP8 and DPP9 activity gave comparable reductions in
cell adhesion and migration as DPP9 depletion, DPP9 may have a more
important role than DPP8 in Huh7 cell movement. Furthermore, the
impairment of cell adhesion and migration could be largely attributed
to DPP8/DPP9 enzyme activity. Until a selective DPP9 inhibitor becomes
available, it remains difﬁcult to differentiate the biological functions
of DPP8 and DPP9. Indeed the down-regulation and enzyme inhibition
of DPP9 in this study target all endogenous DPP9, including both
the short and long forms, in order to understand their biological
functions.
Experiments in which DPP9 levels are manipulated by over-
expression or gene silencing have provided non-concordant data on
cell adhesion and migration. DPP9 over-expression in HEK293T cells
exhibited impaired cell adhesion and wound healing [16], possibly
due to the short form only of DPP9 being over-expressed or alternative-
ly, as a result of the apoptosis induced in those conditions [9,16].
However, we found that Huh7 cells with DPP9 knockdown or DPP9 en-
zyme inhibition were less adhesive and less mobile than their counter-
part control cells, and that apoptosis and cell death in those cells were
unaffected (data not shown).
Mechanistic insights into the role of DPP9 in cell movement are
emerging. We showed the presence of DPP9 at the leading edges of mi-
grating cells, associating with FA proteins integrin-β1 and talin. The ex-
pression of integrin-β1 and talin was decreased when DPP9 was
knocked-down or inhibited. Therefore, it is possible that DPP9 at the
leading edge stabilizes the ability to form focal adhesions, therebymain-
taining adhesiveness and motility. Moreover, previous research has
shown that integrin stimulates FAK phosphorylation at Tyr397 to form
a binding site for Src family kinases, which controls FA turnover [50].
We found that thephosphorylation of FAK at Tyr397was reduced, prob-
ably due to decreased DPP9-driven integrin activation. Paxillin phos-
phorylation is closely coupled to FAK activity and so, in line with the
deactivation of FAK, paxillin phosphorylation at Tyr118 was reduced.
The concomitant decrease in the phosphorylation of FAK and paxillin
strongly indicates that DPP9 depletion or enzyme inhibition suppresses
the associated adhesion signaling pathway, resulting in impaired cell
movement. In addition to FAK and paxillin, it could be informative to as-
sess if DPP9 affects the upstream effectors of the FAK signaling complex,
as well as other integrin-mediated tyrosine kinase signaling pathways.This study provides in vitro data on the biological function of DPP9,
showing that DPP9 knockdown and activity inhibition reduce cell
adhesion and migration, indicating that DPP9 might be a potential
therapeutic target for limiting tumor growth andmetastasis. The recent
discovery of potential DPP9 substrates that have roles in cancer cell
metabolism [47] also points towards the potential of DPP9 inhibition
as a cancer therapy. However, selective inhibitors targeting DPP9 only
and conditional DPP9 knock-out mice would greatly facilitate future
investigations. More explorations are needed to gain in-depth under-
standing of the biological function of DPP9 in tumor biology and the
underlying mechanisms.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.11.029.
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